A Phase Ib/II Trial to Validate the Safety and Efficacy of Zabinostat (CXD101) Monotherapy in Patients with Multiple Tumour Types and Peripheral T-cell lymphoma (PTCL)
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Zabinostat (Primary)
- Indications Peripheral T-cell lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Nuance Biotech
- 05 Jan 2023 According to a Celleron Therapeutics media release, Celleron Therapeutics has merged with the Argonaut Therapeutics to form IngenOx Therapeutics (www.ingenox.com).
- 29 Jun 2022 According to a Celleron Therapeutics media release, the company expect to initiate this trial in 2022.
- 02 Mar 2020 According to a Celleron Therapeutics media release, a peripheral T-cell lymphoma (PTCL) Phase II trial will start in 2020 in China.